• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌的盆腔后切除术:手术和肿瘤学结果。

Posterior pelvic exenteration for ovarian cancer: surgical and oncological outcomes.

机构信息

Institut Paoli Calmettes, Department of Surgical Oncology, Marseille, France.

Faculty of Medical Sciences, Aix-Marseille University, CNRS, Inserm, CRCM, Marseille, France.

出版信息

J Gynecol Oncol. 2022 May;33(3):e31. doi: 10.3802/jgo.2022.33.e31. Epub 2022 Feb 4.

DOI:10.3802/jgo.2022.33.e31
PMID:35320883
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9024184/
Abstract

OBJECTIVE

Posterior pelvic exenteration (PPE) can be required to achieve complete resection in ovarian cancer (OC) patients with large pelvic disease. This study aimed to analyze morbidity, complete resection rate, and survival of PPE.

METHODS

Ninety patients who underwent PPE in our Comprehensive Cancer Center between January 2010 and February 2021 were retrospectively identified. To analyze practice evolution, 2 periods were determined: P1 from 2010 to 2017 and P2 from 2018 to 2021.

RESULTS

A 82.2% complete resection rate after PPE was obtained, with rectal anastomosis in 96.7% of patients. Complication rate was at 30% (grade 3 in 9 patients), without significant difference according to periods or quality of resection. In a binary logistic regression adjusted on age and stoma, only age of 51-74 years old was associated with a lower rate of complication (odds ratio=0.223; p=0.026). Median overall and disease-free survivals (OS and DFS) from initial diagnosis were 75.21 and 29.84 months, respectively. A negative impact on OS and DFS was observed in case of incomplete resection, and on DFS in case of final cytoreductive surgery (FCS: after ≥6 chemotherapy cycles). Age ≥75-years had a negative impact on DFS for new OC surgery. For patients with complete resection, OS and DFS were decreased in case of interval cytoreductive surgery and FCS in comparison with primary cytoreductive surgery.

CONCLUSION

PPE is an effective surgical measure to achieve complete resection for a majority of patients. High rate of colorectal anastomosis was achieved without any mortality, with acceptable morbidity and high protective stoma rate.

摘要

目的

在患有大型盆腔疾病的卵巢癌(OC)患者中,为了实现完全切除,可能需要进行后盆腔切除术(PPE)。本研究旨在分析 PPE 的发病率、完全切除率和生存率。

方法

回顾性分析 2010 年 1 月至 2021 年 2 月期间在我院综合癌症中心接受 PPE 的 90 例患者。为了分析实践演变,确定了 2 个时期:P1 期为 2010 年至 2017 年,P2 期为 2018 年至 2021 年。

结果

PPE 后完全切除率为 82.2%,96.7%的患者行直肠吻合术。并发症发生率为 30%(9 例为 3 级),与时期或切除质量无关。在调整年龄和造口的二项逻辑回归中,只有 51-74 岁的年龄与较低的并发症发生率相关(优势比=0.223;p=0.026)。从初始诊断开始的总生存期(OS)和无病生存期(DFS)的中位数分别为 75.21 和 29.84 个月。不完全切除与 OS 和 DFS 呈负相关,最终减瘤手术(FCS:在≥6 个化疗周期后)与 DFS 呈负相关。年龄≥75 岁与新 OC 手术的 DFS 呈负相关。对于完全切除的患者,与原发性减瘤手术相比,间隔减瘤手术和 FCS 会降低 OS 和 DFS。

结论

PPE 是实现大多数患者完全切除的有效手术措施。结直肠吻合术的高成功率,无任何死亡率,可接受的发病率和高保护性造口术率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2226/9024184/f2c25fc2eaa3/jgo-33-e31-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2226/9024184/f2c25fc2eaa3/jgo-33-e31-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2226/9024184/f2c25fc2eaa3/jgo-33-e31-g001.jpg

相似文献

1
Posterior pelvic exenteration for ovarian cancer: surgical and oncological outcomes.卵巢癌的盆腔后切除术:手术和肿瘤学结果。
J Gynecol Oncol. 2022 May;33(3):e31. doi: 10.3802/jgo.2022.33.e31. Epub 2022 Feb 4.
2
En-bloc pelvic resection with concomitant rectosigmoid colectomy and immediate anastomosis as part of primary cytoreductive surgery for patients with advanced ovarian cancer.对于晚期卵巢癌患者,行整块盆腔切除术并同期行直肠乙状结肠切除术及即时吻合术,作为原发性肿瘤细胞减灭术的一部分。
Eur J Gynaecol Oncol. 2014;35(4):400-7.
3
[Postoperative morbidities after modified posterior pelvic exenteration for ovarian cancer].[卵巢癌改良后盆腔脏器清除术后的术后并发症]
Gynecol Obstet Fertil. 2015 May;43(5):342-7. doi: 10.1016/j.gyobfe.2015.03.006. Epub 2015 Apr 18.
4
Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer.肠系膜淋巴结受累在晚期卵巢癌根治性或超根治性手术中行后盆腔脏器清除术患者中的预后作用
Arch Gynecol Obstet. 2018 Apr;297(4):997-1004. doi: 10.1007/s00404-018-4675-y. Epub 2018 Jan 27.
5
Posterior pelvic exenteration and retrograde total hysterectomy in patients with locally advanced ovarian cancer: Clinical and functional outcome.局部晚期卵巢癌患者的后盆腔脏器清除术及逆行全子宫切除术:临床及功能结局
Taiwan J Obstet Gynecol. 2016 Jun;55(3):346-50. doi: 10.1016/j.tjog.2016.04.010.
6
Modified posterior pelvic exenteration with pelvic side-wall resection requiring both intestinal and urinary reconstruction during surgery for ovarian cancer.用于卵巢癌治疗的改良式盆腔后切除术,需要在手术中同时进行肠和尿路重建,以切除骨盆侧壁。
Gynecol Oncol. 2019 Oct;155(1):172-173. doi: 10.1016/j.ygyno.2019.07.015. Epub 2019 Jul 25.
7
Comparison of morbidity and survival between primary and interval cytoreductive surgery in patients after modified posterior pelvic exenteration for advanced ovarian cancer.改良后的后盆腔切除术治疗晚期卵巢癌患者的初次和间隔减瘤术后发病率和生存情况比较。
Int J Gynecol Cancer. 2012 Oct;22(8):1349-54. doi: 10.1097/IGC.0b013e318265d358.
8
Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.新辅助化疗后延迟细胞减灭术治疗晚期上皮性卵巢癌的生存结局。
Int J Gynecol Cancer. 2020 Dec;30(12):1935-1942. doi: 10.1136/ijgc-2020-001658. Epub 2020 Oct 29.
9
A novel classification of posterior pelvic exenteration to assess prognosis in female patients with locally advanced primary rectal cancer: a retrospective cohort study from China PelvEx collaborative.一种用于评估局部晚期原发性直肠癌女性患者预后的新型盆腔廓清术分类:来自中国盆腔廓清协作组的一项回顾性队列研究
Int J Colorectal Dis. 2024 Apr 26;39(1):59. doi: 10.1007/s00384-024-04632-9.
10
Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.晚期上皮性卵巢癌肿瘤减灭术中肠手术和造口形成后的临床特征和结局。
Int J Gynecol Cancer. 2019 Mar;29(3):585-592. doi: 10.1136/ijgc-2018-000154.

引用本文的文献

1
A novel classification of posterior pelvic exenteration to assess prognosis in female patients with locally advanced primary rectal cancer: a retrospective cohort study from China PelvEx collaborative.一种用于评估局部晚期原发性直肠癌女性患者预后的新型盆腔廓清术分类:来自中国盆腔廓清协作组的一项回顾性队列研究
Int J Colorectal Dis. 2024 Apr 26;39(1):59. doi: 10.1007/s00384-024-04632-9.
2
Prognostic Factors and a Predictive Nomogram of Cancer-Specific Survival of Epithelial Ovarian Cancer Patients with Pelvic Exenteration Treatment.盆腔廓清术治疗上皮性卵巢癌患者的预后因素和癌症特异性生存预测列线图。
Int J Clin Pract. 2023 Aug 17;2023:9219067. doi: 10.1155/2023/9219067. eCollection 2023.
3

本文引用的文献

1
30 Years of Experience in the Management of Stage III and IV Epithelial Ovarian Cancer: Impact of Surgical Strategies on Survival.III期和IV期上皮性卵巢癌管理30年经验:手术策略对生存的影响
Cancers (Basel). 2020 Mar 24;12(3):768. doi: 10.3390/cancers12030768.
2
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.ESMO-ESGO 共识会议关于卵巢癌的建议:病理学和分子生物学,早期和晚期,交界性肿瘤和复发性疾病†。
Ann Oncol. 2019 May 1;30(5):672-705. doi: 10.1093/annonc/mdz062.
3
Enhanced recovery after surgery program in older patients undergoing gynaecologic oncological surgery is feasible and safe.
Laparoscopic posterior pelvic exenteration is safe and feasible for locally advanced primary rectal cancer in female patients: a comparative study from China PelvEx collaborative.
腹腔镜盆腔后切除术治疗女性局部晚期原发性直肠癌的安全性和可行性:中国 PelvEx 协作组的一项对比研究。
Tech Coloproctol. 2023 Nov;27(11):1109-1117. doi: 10.1007/s10151-023-02824-z. Epub 2023 May 27.
4
Application of depithelized gracilis adipofascial flap for pelvic floor reconstruction after pelvic exenteration.脱细胞真皮加脂肪筋膜瓣在盆腔廓清术后盆底重建中的应用。
BMC Surg. 2022 Aug 6;22(1):304. doi: 10.1186/s12893-022-01755-0.
5
Posterior pelvic exenteration, a crucial component in the surgeon's toolbox for optimizing surgical cytoreduction for advanced ovarian cancer.后盆腔脏器清除术是外科医生用于优化晚期卵巢癌手术细胞减灭术的重要手段。
J Gynecol Oncol. 2022 May;33(3):e41. doi: 10.3802/jgo.2022.33.e41. Epub 2022 Feb 21.
老年妇科肿瘤患者术后加速康复方案是可行且安全的。
Gynecol Oncol. 2018 Dec;151(3):471-476. doi: 10.1016/j.ygyno.2018.09.017. Epub 2018 Sep 21.
4
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
5
Ovarian cancer statistics, 2018.卵巢癌统计数据,2018 年。
CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29.
6
Posterior pelvic exenteration and retrograde total hysterectomy in patients with locally advanced ovarian cancer: Clinical and functional outcome.局部晚期卵巢癌患者的后盆腔脏器清除术及逆行全子宫切除术:临床及功能结局
Taiwan J Obstet Gynecol. 2016 Jun;55(3):346-50. doi: 10.1016/j.tjog.2016.04.010.
7
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.新诊断的晚期卵巢癌的初次化疗与初次手术(CHORUS):一项开放标签、随机、对照、非劣效性试验。
Lancet. 2015 Jul 18;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6. Epub 2015 May 19.
8
Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.新辅助化疗联合卡铂和紫杉醇治疗不适合初次手术的晚期卵巢癌患者:安全性和有效性。
Gynecol Oncol. 2014 Feb;132(2):287-91. doi: 10.1016/j.ygyno.2013.12.002. Epub 2013 Dec 9.
9
Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.新辅助铂类/紫杉类化疗联合晚期间隔肿瘤细胞减灭术治疗晚期卵巢癌患者的生存结局进展。
Ann Surg Oncol. 2014 Feb;21(2):629-36. doi: 10.1245/s10434-013-3278-x. Epub 2013 Sep 20.
10
Comparison of morbidity and survival between primary and interval cytoreductive surgery in patients after modified posterior pelvic exenteration for advanced ovarian cancer.改良后的后盆腔切除术治疗晚期卵巢癌患者的初次和间隔减瘤术后发病率和生存情况比较。
Int J Gynecol Cancer. 2012 Oct;22(8):1349-54. doi: 10.1097/IGC.0b013e318265d358.